Envista (NYSE:NVST) Given New $19.00 Price Target at JPMorgan Chase & Co.

Envista (NYSE:NVST - Free Report) had its target price trimmed by JPMorgan Chase & Co. from $20.00 to $19.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages also recently issued reports on NVST. Mizuho assumed coverage on Envista in a report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 price target for the company. Needham & Company LLC reiterated a "hold" rating on shares of Envista in a research note on Thursday. Piper Sandler lifted their price objective on shares of Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Jefferies Financial Group increased their target price on shares of Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company lifted their price target on Envista from $20.00 to $21.00 and gave the company an "equal weight" rating in a research note on Thursday, February 6th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $20.18.

Remove Ads

Envista Stock Performance

NYSE NVST traded down $0.89 on Thursday, hitting $17.55. 3,168,325 shares of the company's stock traded hands, compared to its average volume of 2,287,146. The firm has a market capitalization of $3.02 billion, a PE ratio of -2.70, a P/E/G ratio of 1.27 and a beta of 1.33. Envista has a 1-year low of $15.15 and a 1-year high of $23.00. The firm's 50-day moving average price is $20.22 and its two-hundred day moving average price is $19.70. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, analysts expect that Envista will post 1 EPS for the current year.

Institutional Trading of Envista

A number of hedge funds have recently bought and sold shares of the business. Ariel Investments LLC increased its holdings in shares of Envista by 6.2% in the fourth quarter. Ariel Investments LLC now owns 12,059,624 shares of the company's stock valued at $232,630,000 after purchasing an additional 699,625 shares during the last quarter. Nuance Investments LLC increased its stake in shares of Envista by 4.4% in the 3rd quarter. Nuance Investments LLC now owns 7,346,534 shares of the company's stock worth $145,168,000 after acquiring an additional 308,221 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Envista by 72.6% during the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company's stock worth $132,223,000 after acquiring an additional 2,882,844 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company's stock valued at $130,440,000 after acquiring an additional 1,089,923 shares during the last quarter. Finally, Gates Capital Management Inc. grew its holdings in shares of Envista by 15.1% in the fourth quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company's stock valued at $90,550,000 after purchasing an additional 615,577 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.